Jazz's Xyrem positive in second Phase III fibromyalgia trial
This article was originally published in Scrip
Executive Summary
Jazz Pharmaceuticals' second Phase III trial of Xyrem (sodium oxybate) for fibromyalgia has met its primary endpoint, according to top-line results. The findings match previously reported full results from a US-based Phase III trial (scripnews.com, June 15th, 2009).